PPE For The People will donate personal protective equipment to workers in communities disproportionately affected by COVID-19. Photos via houston.impacthub.net/ppeforthepeople

Through a collaboration between a 3D printing company and a nonprofit organization, small businesses in underserved parts of town are able to apply to receive personal protective equipment donations.

Impact Hub Houston and re:3D have teamed up for an initiative called PPE For The People that will create and donate PPE to small businesses disproportionately affected by the coronavirus outbreak.

"All of the emerging data indicates that, while a coronavirus may not discriminate, disparities that already exist in society are putting communities of color at a disproportionately higher risk of infection, serious illness, and death from COVID-19," says Grace Rodriguez, CEO and executive director of Impact Hub Houston.

According to a news release, the initiative will support workers across industries — from restaurants employees and bus and delivery drivers to small businesses that seek to reopen safely, like barbershops and nail salons.

Impact Hub Houston works to prioritize inclusion in Houston, which has been recognized as the most diverse city in the nation.

"There a number of societal factors that are leading to disproportionately higher COVID-19 cases and deaths among minority communities," says Rodriguez, specifying that these factors include lack of access to health care, overrepresentation of people of color in jobs considered essential, and more.

To start, the initiative has identified the southeast, south, and southwest parts of Houston to deliver four types of 3D-printed PPE: face shields, ear savers, hands-free door opener, and splash guards.

"re:3D has extensively researched PPE production for COVID-19 throughout the crisis as well as collaborated with healthcare workers, first responders, and local businesses to identify where there are gaps in their ability to protect themselves and their customers," says re:3D's community liaison, Charlotte Craff. "We have started with these items because we are confident they fill those needs."

The campaign, which is raising money and seeking volunteers online, began Wednesday, May 6, and expects to deliver its first PPE next week. The organizations are looking into expanding the PPE offered, as well as their reach, but it depends on fundraising.

"We would like to expand the project to serve communities in the northeast and other high-risk areas of Houston, but that all depends on how much funding we can raise to keep producing and delivering PPE," Rodriguez explains.

According to the release, Impact Hub Houston is financially supporting the initiative through its Fiscal Sponsorship Program, which re:3D applied to. The H-Force network, a crisis collaboration, is also lending its support to this initiative.

"We are honored to help those who are most vulnerable," says Craff in the release. "Data from the CDC has shown minority communities are at greater risk of critical illness from COVID-19, and we want to help local small businesses protect their employees as best as possible without it being an added financial burden on already strained industries."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”